TB Prediction / Quantiferon Substudy

Tuberculosis is a major opportunistic infection in HIV-infected patients and approximately 5-10% of patients enrolled in EARNEST were expected to develop tuberculosis over the course of the trial. Unfortunately, management of tuberculosis on second-line therapy is complicated due to major interactions between anti-tuberculosis drugs and boosted protease inhibitors, the cornerstone of second-line therapy. It is hence of clinical importance to be able to predict which patients are most at risk of developing tuberculosis and the primary aim of this substudy is to determine whether the Quantiferon IGRA test can be used to establish this. All sites are participating in this substudy.

© EARNEST - All rights reserved | In collaboration with